What is it about?

Chemotherapy protocols for childhood cancers are still problematic due to the high toxicity associated with chemotherapeutic agents and incorrect dosing regimens extrapolated from adults. Nanotechnology has demonstrated significant ability to reduce toxicity of anticancer compounds. Improvement in the therapeutic index of cytostatic drugs makes this strategy an alternative to common chemotherapy in adults. However, the lack of nanomedicines specifically for pediatric cancer care raises a medical conundrum. This review highlights the current state and progress of nanomedicine in pediatric cancer and discusses the real clinical challenges and opportunities.

Featured Image

Read the Original

This page is a summary of: Nanomedicines for Pediatric Cancers, ACS Nano, August 2018, American Chemical Society (ACS), DOI: 10.1021/acsnano.8b03684.
You can read the full text:



The following have contributed to this page